Featured Research

from universities, journals, and other organizations

Potential new target for antibiotics against E. coli, other bugs

Date:
July 10, 2014
Source:
Ohio State University
Summary:
Scientists have identified a protein that is essential to the survival of E. coli bacteria, and consider the protein a potential new target for antibiotics. E. coli is part of the gram-negative family of bacteria, characterized by having an extra membrane, called the outer membrane, that reduces the chances for a drug to penetrate the cell to kill it. Inhibiting this protein, however, would require getting past just one of the two membranes, meaning it could be an attractive new target for antibiotics in this age of resistant pathogens.

Scientists have identified a protein that is essential to the survival of E. coli bacteria, and consider the protein a potential new target for antibiotics.

Related Articles


In the study, the researchers confirmed that this protein, called MurJ, flips a fatty molecule from one side of a bacterial cell membrane to the other. If that molecule isn't flipped, the cell cannot construct a critical layer that keeps pressurized contents of the cell contained. If those contents aren't contained, the cell bursts.

E. coli is part of the gram-negative family of bacteria, characterized by having an extra membrane, called the outer membrane, that reduces the chances for a drug to penetrate the cell to kill it. Inhibiting MurJ, however, would require getting past just one of the two membranes, meaning it could be an attractive new target for antibiotics in this age of resistant pathogens.

"We have proof of principle that MurJ is actually a valid target because we showed that if we stop it from working, the cells will die within 10 minutes -- very quickly," said Natividad Ruiz, assistant professor of microbiology at The Ohio State University and a co-lead author of the study.

"If you want to develop an antibiotic, it's important to know a protein's function. Defining the activity associated with MurJ is a big step forward toward possibly designing antibiotics that could target it."

Ruiz co-led the study with Thomas Bernhardt, associate professor of microbiology and immunobiology at Harvard Medical School. The research is published in the July 11, 2014, issue of the journal Science.

This work zeroes in on trying to stop construction of a bacterial cell layer called peptidoglycan, a mesh-like structure that, in gram-negative bacteria like E. coli, rests between the inner and outer cell membranes. Without this layer, E. coli cells can't survive.

Scientists have long known most of the steps behind the creation of this layer, which consists of sugars and amino acids cross-linked with each other. But one detail has remained elusive: which protein could get a specific lipid required for building the peptidoglycan layer to change its location, from the inside of the inner membrane to the outside of that membrane, where the peptidoglycan construction is under way.

Lipids contain fat and other substances and serve as part of a cell membrane's infrastructure. The mystery protein has been referred to as a flippase because of its function: flipping the lipid.

About 25 years ago, other groups of scientists proposed two likely proteins that fulfilled this role based on their locations in the bacterial cell. The proteins were known to contribute to construction of the peptidoglycan, but their specific function was never demonstrated.

While investigating cell membranes as a postdoctoral researcher, Ruiz narrowed in on the potential of the MurJ protein to serve as the E. coli flippase.

Ruiz and colleagues have previously shown that MurJ has several features that point to this possibility: A model of its structure shows the characteristic cavity that a flippase needs to have; eliminating the protein showed that cells wouldn't make the peptidoglycan layer; and it was demonstrated to be related to other flipping proteins.

In this new work, the labs led by Ruiz and Bernhardt combined to take the additional steps needed to confirm MurJ's function.

One step that was important to Ruiz was being able to stop MurJ's work in the cells and see the immediate effects of that inhibition. With most research like this, scientists lower protein levels by suppressing activation of the genes that make the protein -- which takes time and doesn't necessarily fully eliminate the protein's presence.

Ruiz's lab instead used a synthetic chemical to bind to hotspots on MurJ in cells in ways that immediately stopped the protein from functioning.

"The idea is to inhibit the protein, and then -- boom -- analyze it and see whether you're stopping the flipping," Ruiz said. "It's the equivalent to using an antibiotic that would kill the protein by not allowing it to work when it binds."

Bernhardt's lab then developed a way to further test the effects of inhibiting MurJ. The researchers used a toxin some cells release that is known to "eat" the flipped lipid shortly after it appears on the outside of its inner membrane, effectively halting construction of the peptidoglycan.

In normal cells, very little of the target lipid could be detected when the toxin was inserted into the cells, meaning the lipid was being flipped and immediately consumed by the toxin. But when MurJ was inhibited in those cells and the toxin was added, the scientists detected a buildup of the lipid that the toxin could not eat -- meaning that the lipid never got flipped because the activity of MurJ was gone.

"We showed these cells will die if we inhibit MurJ and we showed that MurJ is required for flipping to occur. If the cells are dying because the flipping doesn't occur, then nobody else is doing that job. This is the one," Ruiz said, explaining that MurJ is the mystery flippase.


Story Source:

The above story is based on materials provided by Ohio State University. The original article was written by Emily Caldwell. Note: Materials may be edited for content and length.


Journal Reference:

  1. L.-T. Sham, E. K. Butler, M. D. Lebar, D. Kahne, T. G. Bernhardt, N. Ruiz. MurJ is the flippase of lipid-linked precursors for peptidoglycan biogenesis. Science, 2014; 345 (6193): 220 DOI: 10.1126/science.1254522

Cite This Page:

Ohio State University. "Potential new target for antibiotics against E. coli, other bugs." ScienceDaily. ScienceDaily, 10 July 2014. <www.sciencedaily.com/releases/2014/07/140710141351.htm>.
Ohio State University. (2014, July 10). Potential new target for antibiotics against E. coli, other bugs. ScienceDaily. Retrieved November 1, 2014 from www.sciencedaily.com/releases/2014/07/140710141351.htm
Ohio State University. "Potential new target for antibiotics against E. coli, other bugs." ScienceDaily. www.sciencedaily.com/releases/2014/07/140710141351.htm (accessed November 1, 2014).

Share This



More Plants & Animals News

Saturday, November 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Watch Baby Goose Survive A 400-Foot Cliff Dive

Watch Baby Goose Survive A 400-Foot Cliff Dive

Buzz60 (Oct. 31, 2014) For its nature series Life Story, the BBC profiled the barnacle goose, whose chicks must make a daredevil 400-foot cliff dive from their nests to find food. Jen Markham has the astonishing video. Video provided by Buzz60
Powered by NewsLook.com
World's Salamanders At Risk From Flesh-Eating Fungus

World's Salamanders At Risk From Flesh-Eating Fungus

Newsy (Oct. 31, 2014) The import of salamanders around the globe is thought to be contributing to the spread of a deadly fungus. Video provided by Newsy
Powered by NewsLook.com
Alcoholic Drinks In The E.U. Could Get Calorie Labels

Alcoholic Drinks In The E.U. Could Get Calorie Labels

Newsy (Oct. 31, 2014) A health group in the United Kingdom has called for mandatory calorie labels on alcoholic beverages in the European Union. Video provided by Newsy
Powered by NewsLook.com
Malaria Threat in Liberia as Fight Against Ebola Rages

Malaria Threat in Liberia as Fight Against Ebola Rages

AFP (Oct. 31, 2014) Focus on treating the Ebola epidemic in Liberia means that treatment for malaria, itself a killer, is hard to come by. MSF are now undertaking the mass distribution of antimalarials in Monrovia. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Plants & Animals

Earth & Climate

Fossils & Ruins

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins